|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2002-12-17
|
|
pubmed:abstractText |
Fenfluramine-derivative diet pills were withdrawn from the market in 1997 because of an association with valvular regurgitation, but subsequent estimates of the prevalence of this condition have varied widely. We systematically reviewed evidence regarding the prevalence of valvular disease after fenfluramine exposure.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1097-6744
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
144
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1065-73
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies.
|
|
pubmed:affiliation |
Duke Clinical Research Institute and the School of Medicine, Duke University, Durham, NC, USA. ms3@duke.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Review,
Meta-Analysis
|
